| Document |
Document Title |
|
WO/2024/089153A1 |
The present invention relates to a method for the genome editing of cells at a target locus by homology directed repair (HDR) within a cell population and concurrently enriching within said cell population the HDR-genome edited cells, wh...
|
|
WO/2024/090562A1 |
Provided is a method for producing a glutamate dehydrogenase of which the coenzyme is FAD. Also provided is a FAD-dependent glutamate dehydrogenase having a specified amino acid substitution.
|
|
WO/2024/091958A1 |
Provided herein are compositions, systems, and methods comprising guide nucleic acids and uses thereof with CRISPR-associated (Cas) proteins. Various compositions, systems, and methods of the present disclosure may leverage the activitie...
|
|
WO/2024/091701A1 |
Provided herein are compositions and methods for tissue repair. In particular, the compositions and methods described herein find use in repairing, regenerating, and modulating fibrosis and inflammation in a variety of tissues such as, f...
|
|
WO/2024/092001A1 |
The present disclosure provides methods for preventing or treating Alzheimer's disease in a subject, and/or reducing the likelihood or severity of Alzheimer's disease comprising administering to the subject an effective amount of an anti...
|
|
WO/2024/091775A1 |
Provided are variant Cas12f4 polypeptides, fusion proteins containing variant Cas12f4 polypeptides, nucleic acids encoding variant Cas12f4 polypeptides and fusion proteins, compositions and methods related to those variant Cas12f4 polype...
|
|
WO/2024/089274A2 |
Provided herein are novel compositions and methods for treating melanocytic disease. Provided herein are novel compositions and methods of treating diseases arising from gain-of-function NRAS and BRAF variants including cancer, in partic...
|
|
WO/2024/091299A1 |
Described herein are methods for disease or disorder associated with GABA transporter 1 (GAT-1) dysfunction. In one aspect described herein, the disease or disorder is associated with one or more solute carrier Family 6 Member 1 (SLC6A1)...
|
|
WO/2024/087761A1 |
The present invention relates to a method for producing a polypeptide from a recombinant fusion protein, and disclosed are a method for producing a polypeptide by means of serially combining multiple protease cleavage sites and polypepti...
|
|
WO/2024/088342A1 |
Described herein are CD24 binding antibodies and fragments thereof.
|
|
WO/2024/089131A1 |
The present invention is in the technical field of synthetic biology, metabolic engineering and cell cultivation. The present invention provides a cell for the production of one or more bioproduct(s) wherein the cell is capable to produc...
|
|
WO/2024/089633A1 |
The present disclosure relates to RNA molecules encoding a respiratory syncytial virus (RSV). The present disclosure further relates to compositions comprising the RNA molecules formulated in a lipid nanoparticle (RNA-LNP). The present d...
|
|
WO/2024/091579A2 |
Nucleic acid payload delivery systems, and related compositions and kits are provided. Aspects of such systems, compositions, and kits include lipid nanoparticle (LNP)-complexed payload DNAs and auxiliary RNAs. In some instances, the DNA...
|
|
WO/2024/091908A1 |
Aspects of the disclosure relate to compositions, such as isolated nucleic acids (e.g., packing nucleic acids) comprising one or more hairpin-forming nucleic acids positioned 5' and/or 3', and/or in between the Rep and Cap gene. The disc...
|
|
WO/2024/092151A1 |
Provided herein is a method for analyzing cells. In some embodiments the method may comprise base editing a target gene in a population of cells to produce genetically modified cells, reverse transcribing mRNA from single cells in the po...
|
|
WO/2024/092187A2 |
Described are CRISPR constructs and systems that can be used to generate Phytophthora crown rot resistant strawberry cultivars rapidly and efficiently.
|
|
WO/2024/089011A1 |
The present invention is in the field of plant molecular biology and is directed to excision of recombinant DNA from the genome of plant somatic cells.
|
|
WO/2024/087370A1 |
The present invention relates to the technical field of molecular biology, and provides a preparation method for a eukaryotic expression-based deoxynivalenol full-length antibody and a use of a eukaryotic expression-based deoxynivalenol ...
|
|
WO/2024/092226A1 |
The present invention provides an oligomer capable of binding to a target site of precursor messenger RNA (pre-mRNA) of myosin phosphatase target subunit (Mypt1) in cells, wherein binding of the oligomer to the target site of the pre-mRN...
|
|
WO/2024/086949A1 |
A method of isolating and purifying double stranded RNA (dsRNA) from a sample includes treating a crude RNA extract containing dsRNA obtained from a sample with a B2 dsRNA-binding protein to form a B2-dsRNA mixture containing a B2-dsRNA ...
|
|
WO/2024/088309A1 |
Provided are a multispecific antibody binding to GPRC5D and CD3 antigens, an antigen binding molecule thereof, a nucleic acid molecule encoding the multispecific antibody and the antigen binding molecule thereof, a vector containing the ...
|
|
WO/2024/086928A1 |
The present disclosure generally relates to binding agents that are capable of targeting tumor cells and/or immune cells and their use for treating cancer. The binding agents of the present disclosure comprise one or more antigen binding...
|
|
WO/2024/088424A1 |
Provided in the present disclosure is an antibody specifically binding to cytotoxic T lymphocyte-associated antigen-4 (CTLA4), particularly a heavy-chain antibody, and more particularly a single-domain antibody. Also disclosed is the the...
|
|
WO/2024/088390A1 |
The present invention provides a preparation containing an anti-Nectin-4 antibody drug conjugate (ADC) and a use thereof. The preparation comprises an ADC, a buffering agent and an excipient. The anti-Nectin-4 ADC in the preparation exis...
|
|
WO/2024/088176A1 |
The present invention relates to the field of biomedicine, and mainly relates to a vaccine design method for enhancing an antigen-presenting effect, which is applied to structural sequence design and preparation of nucleic acids, protein...
|
|
WO/2023/240050A9 |
The disclosure relates to compounds and methods for repurposing antibodies.
|
|
WO/2024/091979A1 |
The invention relates generally to engineered anti-CD276 antibodies containing one or more unnatural amino acids (UAAs), their conjugation with a payload to generate an antibody-payload (e.g., drug) conjugate, drug substances containing ...
|
|
WO/2024/091907A1 |
Provided herein are compositions, systems, and methods comprising effector proteins for treating HPV infections. These effector proteins may be characterized as CRISPR-associated (Cas) proteins. Various compositions, systems, and methods...
|
|
WO/2024/091578A2 |
Methods of nuclear targeted DNA delivery are provided. Aspects of the methods include contacting a cell with: (a) a nuclear targeted deoxyribonucleic acid (NTDNA) that includes a DNA nuclear targeting sequence (DTS) and a cargo nucleic a...
|
|
WO/2024/090893A1 |
The present invention relates to extracellular vesicles (EVs) overexpressing fibronectin fragment protein, and a use for drug delivery thereof. The present invention relates to a method for increasing EV delivery efficiency into cells by...
|
|
WO/2024/088401A1 |
Provided are gene editing systems and methods for reducing cell immunogenicity and reducing graft versus host (GvH) response, or to promote the persistence of therapeutic cells. Also provided are polynucleotides, vectors, cells, kits and...
|
|
WO/2024/089629A1 |
An engineered, non-naturally occurring Cas12 protein, CRISPR-Cas system and uses thereof are provided. The engineered, non-naturally occurring novel Cas12 proteins comprise an amino acid sequence selected from SEQ ID NOs: 1-36, a homolog...
|
|
WO/2024/091053A1 |
The present invention relates to a method for predicting the response to immunotherapeutic agents, comprising a step of measuring, in cancer cells or cancer tissue, the expression level of a dexamethasone-induced ras-related protein 1 (D...
|
|
WO/2024/091540A1 |
The present disclosure relates to compositions and methods for the suppression of silencing of a gene of interest in plants. Also disclosed are vectors, transgenic plants and plant parts comprising genetic constructs for suppressing endo...
|
|
WO/2024/092199A1 |
The present disclosure provides polypeptide molecules comprising one or more polypeptide chains and systems, compositions, and methods of use thereof, wherein the polypeptide molecule comprising one or more polypeptide chains (or enginee...
|
|
WO/2024/091694A1 |
A chimeric protein encoded by an expression plasmid is provided. The chimeric protein comprises an extracellular of a pathogen-binding receptor and an intracellular domain of an innate immune signaling protein, such as the TLR family of ...
|
|
WO/2024/089634A1 |
The present disclosure relates to compositions comprising RNA molecules encoding an antigen derived from influenza, wherein the RNA is formulated in a lipid nanoparticle (LNP), and wherein the composition further includes a polypeptide a...
|
|
WO/2024/088435A1 |
Provided is a Pseudomonas sp. having a mutant of PHA polymerase PhaC61-3. The Pseudomonas sp. is fermented to produce a novel viscous polyhydroxyalkanoate, providing a new material for the preparation of degradable products.
|
|
WO/2024/087515A1 |
Provided are an anti-CD16A antibody and an application thereof. The antibody comprises heavy chain variable region CDR1, CDR2 and CDR3 sequences as shown in SEQ ID NOs: 1, 2 and 3 respectively, or amino acid sequences at least 95% identi...
|
|
WO/2024/090383A1 |
Provided is a production method of cells into which exogenous mitochondria have been introduced, the production method comprising culturing recipient cells using cell culture equipment in which mitochondria isolated from donor cells are ...
|
|
WO/2024/092258A2 |
Disclosed herein are novel transcription factors for promoting reprogramming of, and/or for direct conversion of, an astrocyte to a neuron. Further provided are polynucleotides encoding the transcription factors, as well as DNA targeting...
|
|
WO/2024/090872A1 |
The present invention relates to a method and a kit for rapidly diagnosing tsutsugamushi on the basis of genetic scissors. More specifically, the present invention relates: to a molecular diagnosis method for rapidly detecting Orientia t...
|
|
WO/2024/088325A1 |
The present invention relates to an antibody that specifically binds to CLDN6, and the use thereof.
|
|
WO/2023/056252A9 |
Multispecific binding proteins that bind NKG2D receptor, CD 16, and B cell-activating factor receptor (BAFF-R) are described, as well as pharmaceutical compositions and therapeutic methods of the multispecific binding proteins useful for...
|
|
WO/2024/092217A1 |
The present disclosure provides systems and methods for high throughput genetic manipulation. Particularly, systems and methods are provided for scalable gene insertions in mammalian cells, the systems and methods comprise a donor nuclei...
|
|
WO/2024/088808A1 |
Provided are compositions containing microalgae extracellular vesicles (MEVs) formulated for intranasal delivery, whereby, upon intranasal administration the MEVs traffic through specific routes following intranasal administration to spe...
|
|
WO/2024/086919A1 |
The present disclosure provides antibodies or antigen-binding fragments thereof that bind specifically to integrin α11 (ITGA11). This disclosure also provides methods for treating a disorder in a subject, such as a fibrotic disorder, an...
|
|
WO/2024/090884A1 |
The present invention relates to a novel phenylalanine:H+ symporter PheP variant and a method for producing L-aromatic amino acids using same, wherein the protein activity of the phenylalanine:H+ symporter PheP variant changes as at leas...
|
|
WO/2024/092095A1 |
Provided herein are methods and compositions for the diagnosis, prognosis, and treatment of a vascular disease, such as coronary artery disease (CAD), in a subject. In particular, provided are methods and compositions for treating a vasc...
|
|
WO/2024/090455A1 |
A multiple sclerosis diagnostic method according to the present invention comprises: a step for measuring the relative abundance of a bacterium contained in a saliva sample collected from a subject; and a step for performing (1) or (2) b...
|
